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Background
 Non-primary percutaneous coronary intervention (non-PPCI), or elective PCI, is defined 
as PCI for indications aside from ST-elevation myocardial infarction (STEMI), cardiac 
arrest, or cardiogenic shock
 Performance of non-PPCI at centers with cardiac surgery backup on-site has been 
under investigation, with the role of surgical presence remaining on ongoing debate
 2011 ACC/AHA/SCAI Guideline for Percutaneous Coronary Intervention upgraded the 
recommendation for non-PPCI at facilities without on-site surgical support to Class IIb, 
as long as appropriate systems of care were developed and rigorous clinical and 
angiographic criteria were used for proper patient selection
 The use of centers without on-site cardiac surgery initially developed as a means to 
improve:
 Door-to-balloon time and clinical outcomes in STEMI patients
 Improve geographic expansion of cardiologic services to increase access in underserved 
areas
 Economic factors 
 State of Michigan approved the performance on non-PPCI at certificate of need 
(CON) centers in March 2016. Prior to this, centers without surgical support were only 
approved to perform primary PCI
Methods
 Data Source
 Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)
 All non-PPCI cases between April 2016 to March 2018 included
 33 hospitals with on-site surgery and 14 hospital without on-site surgery included
 Primary Outcome: 
 Composite of all-cause, in-hospital mortality, contrast-induced nephropathy, NCDR defined 
bleeding, major bleeding, and stroke 
 Secondary Outcomes: 
 All-cause in-hospital mortality, major bleeding, RBC/whole blood transfusion, any bleeding 
event within 72 hours of PCI, other vascular complications requiring transfusion, CVA/stroke, 
heart failure, Q-wave myocardial infarction, subacute stent thrombosis, repeat PCI to same 
lesion, cardiac tamponade, new requirement for dialysis, urgent/emergent CABG, contrast-
induced nephropathy (CIN), and length of stay
 Statistics
 1:1 propensity score matching using logistic regression models adjusting for over 20 clinical 
and demographic variables to create matched cohorts of non-PPCI cases at sites with and 
without on-site surgery  --> 4,463 matched patients
 Baseline demographic, clinical and procedural variables, and in-hospital outcomes 
compared
 Absolute standardized difference threshold of >10% was used as a marker for clinically 
meaningful differences

All PCI Cases Non-PPCI Cases
Trends and Site-specific Distribution of PCI in the State of Michigan During the Study Period 
on a Quarterly Basis 
Trends in Volume Ramp-Up of Non-PPCI at Sites Without Surgery During the First 
12 Months Post-Approval
Sites with Surgery %Cases Sites Without Surgery %Cases P-value ASD (%)
N = 4,643   
Demographics
Age, years 65.3 ± 11.9 65.0 ± 11.5 p = 0.184 2.75
Male 3,145 67.70% 3,023 65.10% p = 0.008 5.54
White 3,909 84.20% 4,066 87.60% p < 0.001 9.78
Clinical History
Hypertension 4,087 88.00% 3,960 85.30% p < 0.001 8.01
Dyslipidemia 3,816 82.20% 3,592 77.40% p < 0.001 12.09
Diabetes Mellitus 1,917 41.30% 1,899 40.90% p = 0.704 0.79
Current/Recent Smoker (<1 year) 1,221 26.30% 1,297 27.90% p = 0.076 3.68
Prior Myocardial Infarction 1,674 36.10% 1,561 33.60% p = 0.014 5.1
Prior PCI 2,261 48.70% 2,029 43.80% p < 0.001 9.9
Prior CABG 824 17.80% 522 11.30% p < 0.001 18.53
Prior Heart Failure 915 19.70% 764 16.50% p < 0.001 8.45
Chronic Lung Disease 821 17.70% 810 17.50% p = 0.768 0.61
Currently on Dialysis 136 2.90% 135 2.90% p = 0.948 0.14
Cerebrovascular Disease 733 15.80% 589 12.70% p < 0.001 8.89
Contrast Volume, mean mL + SD 157.1 ± 66.4 161.1 ± 66.8 p = 0.004 5.97
Vessel Intervened Upon
Left Main 154 3.30% 49 1.10% p < 0.0001 15.51
Left Anterior Descending 2072 44.60% 2019 43.50% p = 0.2771 2.28
Left Circumflex 1366 29.40% 1256 27.10% p = 0.0197 5.25
Right Coronary Artery 1534 33.00% 1536 33.10% p = 0.9648 0.11
Bypass Graft 249 5.40% 162 3.50% p = 0.0001 9.12
Chronic Total Occlusion 228 4.90% 88 1.90% p < 0.0001 16.69
Bifurcation 368 7.90% 375 8.10% p = 0.7890 0.56
Sites with 
Surgery
%Cases
Sites 
Without 
Surgery
%Cases P-value ASD (%)
N = 4,643
MACE 119 2.6% 131 2.8% p = 0.443 1.60
In-Hospital Mortality 26 0.6% 21 0.5% p = 0.465 1.52
Major Bleeding 19 0.5% 14 0.4% p = 0.728 1.10
RBC/Whole Blood Transfusion 61 1.3% 53 1.1% p = 0.452 1.56
Bleeding Event Within 72 hrs 82 1.8% 106 2.3% p = 0.077 3.68
Other Vascular Complications 
Requiring Transfusion 14 0.3% 7 0.2% p = 0.126 3.17
CVA/Stroke 19 0.4% 6 0.1% p = 0.009 5.41
Cardiogenic Shock 37 0.8% 41 0.9% p = 0.647 0.95
Heart Failure 87 1.9% 49 1.1% p = 0.001 6.81
Subacute Stent Thrombosis 5 0.1% 6 0.1% p = 0.774 0.63
Repeat PCI (same lesion) 15 0.3% 8 0.2% p = 0.210 3.03
Cardiac Tamponade 8 0.2% 4 0.1% p = 0.248 2.40
New Requirement for Dialysis 6 0.1% 5 0.1% p = 0.763 0.62
CABG (urgent/emergent status) 22 0.5% 15 0.3% p = 0.250 2.39
Contrast-Induced Nephropathy 72 1.8% 64 1.9% p = 0.795 0.61
Length of Stay (days) 2.8 ± 5.6 2.6 ± 3.0 p = 0.117 3.25
Discussion
• Non-primary, or elective, PCI at sites without on-site cardiac surgery can be 
safely performed with no significant differences in in-hospital mortality and 
complication rates, when compared to sites with on-site surgery
• With regards to important quality measures, there were no statistically significant 
differences in rates of CIN, major bleeding, transfusion requirements, length of 
stay, or urgent/emergent CABG
• Even after exclusion of high risk cases (EF<30%, left main intervention, CTO, 
bifurcation lesions, or use of atherectomy devices) to create “truly elective 
cases” there were no differences in outcomes
• Furthermore, while small in number (651 matched patients), the outcomes of these 
“high risk” cases were also similar with no major differences at the two sites
• The use of a robust system of data collection, auditing and quality improvement 
may provide a template for ensuring safe and optimal expansion of PCI 
services across centers with no cardiac surgery on site 
• Is it time to readdress the guideline recommendations….?
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